Physiology and pathophysiology of the 5-HT3 receptor
- PMID: 15515404
Physiology and pathophysiology of the 5-HT3 receptor
Abstract
The 5-HT3 receptor is a ligand-gated cation channel located in the central and peripheral nervous system; it has also been detected on a variety of other cells. In the periphery, it is found on autonomic neurons and on neurons of the sensory and enteric nervous system. In the CNS, the 5-HT3 receptor has been localized in the area postrema, nucleus tractus solitarii, nucleus vaudatus, nucleus accumbens, amygdala, hippocampus, entorhinal, frontal, cingulate cortex, and in the dorsal horn ganglia. Further extraneuronal locations include among others lymphocytes, monocytes, and foetal tissue. 5-HT3 receptors modulate the release of neurotransmitters and neuropeptides like dopamine, cholecystokinin, acetylcholine, GABA, substance P, and serotonin itself. They have been demonstrated to be involved in sensory transmission, regulation of autonomic functions, integration of the vomiting reflex, pain processing and control of anxiety. While the physiologic functions of the 5-HT3 receptor are discrete and difficult to detect, it plays a key role in certain pathologic situations related to increased serotonin release. Clinical development of 5-HT3 receptor antagonists revealed a remarkable range of activities. 5-HT3 receptor antagonists do not modify any aspect of normal behaviour in animals or induce pronounced changes of physiological functions in healthy subjects. Clinical efficacy was shown for various forms of emesis like chemotherapy-induced, radiotherapy-induced, and postoperative emesis, diarrhoea-predominant irritable bowel syndrome, anxiety, chronic fatigue syndrome, alcohol abuse, and in pain syndromes such as fibromyalgia and migraine. Most recent data also suggest that 5-HT3 receptor antagonists are effective for the treatment of other rheumatic diseases such as rheumatoid arthritis, tendinopathies, periarthropathies, and myofascial pain. Other possible indications under discussion are chronic heart pain and bulimia. Unfortunately, experimental findings do not yet provide a homogenous conception of the significance of 5-HT3 receptors in all investigated fields; in nociception, for example, contradictory observations are still inadequately explained and complicated by bell-shaped dose-response curves. Further elucidation and better understanding of the serotonergic neuronal network remains a task for the next decade.
Similar articles
-
The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.Eur J Pharmacol. 2007 Mar 29;560(1):1-8. doi: 10.1016/j.ejphar.2007.01.028. Epub 2007 Jan 30. Eur J Pharmacol. 2007. PMID: 17316606 Review.
-
Spectrum of use and tolerability of 5-HT3 receptor antagonists.Scand J Rheumatol Suppl. 2004;119:12-8. Scand J Rheumatol Suppl. 2004. PMID: 15515406 Review.
-
Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:3-14. doi: 10.1111/j.1365-2036.2004.02180.x. Aliment Pharmacol Ther. 2004. PMID: 15521849 Review.
-
Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.Scand J Rheumatol Suppl. 2004;119:44-8. Scand J Rheumatol Suppl. 2004. PMID: 15515413 Clinical Trial.
-
Analgesic effects of 5-HT3 receptor antagonists.Scand J Rheumatol Suppl. 2004;119:19-23. Scand J Rheumatol Suppl. 2004. PMID: 15515407 Review.
Cited by
-
The Effect of Ondansetron on Improvement of Symptoms in Patients with Irritable Bowel Syndrome with Diarrhea Domination: A Randomized Controlled Trial.Middle East J Dig Dis. 2024 Jul;16(3):178-184. doi: 10.34172/mejdd.2024.386. Epub 2024 Jul 31. Middle East J Dig Dis. 2024. PMID: 39386337 Free PMC article.
-
Differential distribution of serotonin receptor subtypes in BNST(ALG) neurons: modulation by unpredictable shock stress.Neuroscience. 2012 Dec 6;225:9-21. doi: 10.1016/j.neuroscience.2012.08.014. Epub 2012 Aug 23. Neuroscience. 2012. PMID: 22922122 Free PMC article.
-
The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).Therap Adv Gastroenterol. 2015 May;8(3):136-42. doi: 10.1177/1756283X15572580. Therap Adv Gastroenterol. 2015. PMID: 25949526 Free PMC article. Review.
-
MD-354: what is it good for?CNS Drug Rev. 2007 Spring;13(1):1-20. doi: 10.1111/j.1527-3458.2007.00002.x. CNS Drug Rev. 2007. PMID: 17461887 Free PMC article. Review.
-
Antiemetic activity of abietic acid possibly through the 5HT3 and muscarinic receptors interaction pathways.Sci Rep. 2024 Mar 19;14(1):6642. doi: 10.1038/s41598-024-57173-0. Sci Rep. 2024. PMID: 38503897 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources